There are over 20 subpanels for approximately 400 genes to be reviewed for genes associated with a wide range of diseases
Haegsim Yobeob Enhances Next-Generation Sequencing for Rapid and Cost-Efficient Genetic Screening
Posts Tagged: Biotechnology
Haegsim Yobeob Plans to Open a New Production Unit for Genetic Biopharmaceuticals
Haegsim Yobeob (ISN: KR0925527744), a global provider of gene therapy solutions for a wide range of medical, research, and pharmaceutical applications, is pleased to announce the initiative of launching a new Genetic Biopharmaceutical Production Unit in Busan. The business is developing a pipeline of therapeutic options, some of which are adeno-associated virus (AAV)-based gene therapies,… Read more »
Haegsim-Yobeob to Develop Advanced AAV Gene Therapy Sequences for Cardiac and Skeletal Muscles
Haegsim Yobeob (ISN: KR0925527744), a global provider of gene therapy solutions for a wide range of medical, research, and pharmaceutical applications, recently announced the plan to use the company’s platform to create new adeno-associated virus (AAV) vectors for gene therapy targeted at skeletal and cardiac muscle. The platform is an innovative method for developing novel… Read more »
Haegsim-Yobeob Works on Developing Novel Gene Therapies for Cardiovascular Diseases
Haegsim Yobeob (ISN: KR0925527744), a global provider of gene therapy solutions for a wide range of medical, research, and pharmaceutical applications, is pleased to announce a multi-year global strategic initiative to identify, develop, and commercialize Adeno-Associated Virus (AAV) gene treatments to treat genetic cardiovascular disorders. The initiative will use the company’s integrated AAV gene therapy… Read more »
Haegsim Yobeob to Implement Quality by Design Principles in the Cell-Based Therapy Industry
Haegsim Yobeob (ISN: KR0925527744), a global provider of gene therapy solutions for a wide range of medical, research, and pharmaceutical applications, is pleased to announce the establishment of a multi-stakeholder engagement to apply Quality by Design (QbD) principles to the production of a Chimeric Antigen Receptor T-cell (CAR-T) treatment. The field of cell-based therapy, which… Read more »
